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Abstract
Whereas biological materials were once transferred freely, there has been a marked shift in
the formalisation of exchanges involving these materials, primarily through the use of Mate-
rial Transfer Agreements (MTAs). This paper considers how risk aversion dominates MTA
negotiations and the impact it may have on scientific progress. Risk aversion is often based
on unwarranted fears of incurring liability through the use of a material or loss of control or
missing out on commercialisation opportunities. Evidence to date has suggested that com-
plexity tends to permeate even straightforward transactions despite extensive efforts to
implement simple, standard MTAs. We argue that in most cases, MTAs need do little more
than establish provenance, and any attempt to extend MTAs beyond this simple function
constitutes stifling behaviour. Drawing on available examples of favourable practice, we
point to a number of strategies that may usefully be employed to reduce risk-averse tenden-
cies, including the promotion of simplicity, education of those engaged in the MTA process,
and achieving a cultural shift in the way in which technology transfer office (TTO) success is
measured in institutions employing MTAs.
Introduction
A broad range of biological materials are transferred between laboratories to keep these engine
rooms of innovation ticking. Material Transfer Agreements (MTAs) are common vehicles for
exchanging these materials, whether between laboratories in universities and research insti-
tutes or between these organisations and industry [1]. Convoluted negotiations between insti-
tutional technology transfer offices (TTOs) tend to dominate even straightforward MTA
transactions [2,3,4]. Indiscriminate use of complicated MTAs could unnecessarily slow prog-
ress in the biological sciences, given that very few are ever likely to be enforced [2,3]. Our
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collective experience leads us to conclude that a) the main purpose of written MTAs should
not be to ascribe ownership but simply to establish provenance, the pathway the material takes
from its point of origin; and b) the core problem that interferes with achievement of a) is
unreasonable risk aversion.
MTAs provide clear ‘chains of custody’ by documenting the paths travelled by materials
[5], recording their origins and encumbrances imposed by previous agreements (including
funding agreements), and listing other rights and obligations attaching to them. While MTAs
serve a useful purpose, negotiations due to perceived risks can delay transfers and impose
research impediments [4]. Extended negotiations are often based on overestimated fears of
incurring liability through use, loss of control, or missing out on speculative commercialisa-
tion opportunities [3].
One step that has been taken to streamline MTA processes is the implementation of stan-
dard form agreements [6]. The Simple Letter Agreement (SLA) and Uniform Biological Mate-
rial Transfer Agreement (UBMTA), developed by the National Institutes of Health (NIH) and
the Association of University Technology Managers (AUTM), are a well-documented attempt
to achieve the goal of simplifying exchanges between universities and research institutes. The
number of signatories to the UBMTA suggests that there is widespread support for the imple-
mentation of this initiative. Despite this, many parties are unable to resist the temptation to
tweak agreements, which compels organisations receiving them to carefully examine them for
discrepancies, variations, or anything perceived to disadvantage the interests of their own
institution [1,4,7].
Once we accept that MTAs are a necessary part of the exchange process and that simplify-
ing transfers would increase research efficiency and be a more efficient use of administrative
resources, the challenge is to determine how to improve MTA practices.
Examples of good practice
Structural genomics and computational biology represent areas of research in which there has
been a longstanding commitment to principles of open access. Openness is regarded as techno-
logically important in these fields because of a need to ensure interoperability of bioinformatics
software and promote the development of common ontologies for the virtual expression of bio-
logical concepts. This is evidenced by the large number of bioinformatics software packages that
are available under open source licences and on online open source repositories.
The adoption of open access principles has been less straightforward in other fields. Even
within initiatives specifically designed to facilitate exchanges of materials for research pur-
poses, there is evidence that parties can still unduly complicate the transfer process. An exam-
ple is the Knockout Mouse Project, in which European repositories utilised restrictive terms
for deposit and distribution, flowing, in part, from concerns about use, appropriate attribution
of the source of material, and distribution of profits from commercial exploitation [8]. This led
to frustration and delays rather than systemic failure of the initiative.
Other models have achieved greater success, as illustrated by the examples provided in
Boxes 1 and 2.
Box 1. Addgene
Research utilising Clustered Regularly Interspersed Short Palindromic Repeats
(CRISPR) is providing a significant advance in the development of accurate and safe
editing of the genome of all living organisms. The development of CRISPR technology is
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being facilitated by open distribution of CRISPR reagents, RNA, and plasmids for aca-
demic research use through Addgene, a nonprofit intermediary established specifically
for the purpose of accelerating science by providing access to materials and information
[12].
The process for distribution of CRISPR constructs via Addgene starts with the deposit-
ing scientist’s TTO signing a deposit agreement, which authorises Addgene to distribute
the materials under a standard UBMTA. The requesting scientist’s TTO is required to
complete the MTA and most often does so via Addgene’s custom electronic MTA
(eMTA) signature system. The average turnaround time for Addgene’s eMTA is 2 days.
In this way, one signature can translate into thousands of rapidly executed MTAs. One
of the most important features of the system is the fact that Addgene keeps detailed and
accurate records and makes these transaction records available via online accounts to
both materials depositors and their TTOs. The capability of knowing where all one’s
materials have been distributed is a primary benefit to such a system and one of the most
important aspects of MTA completion. Addgene has facilitated over 200,000 MTAs.
Addgene is currently distributing materials under the UBMTA terms at a rate of over
600 items daily to scientists in over 95 countries. Fig 1 illustrates how demand for
CRISPR constructs through Addgene has grown exponentially.
Addgene has successfully provided a process between researchers to facilitate simple,
efficient, and accurately recorded exchanges of CRISPR materials [13]. However, there is
one note of caution in that not all CRISPR constructs are available through Addgene.
This illustrates a potential difficulty of encouraging basic research for fields with compli-
cated commercial interests [14], particularly for transformative technologies in which
academic and commercial interests collide. It does not necessarily have to be the case
that concurrent transfer of relevant materials for academic research purposes must cease
once there is a commercially promising lead.
Fig 1. Distribution of CRISPR-Related Plasmids (number) by Addgene (cumulative).
https://doi.org/10.1371/journal.pbio.2006031.g001
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What lessons can we take from these examples in shaping strategies to facilitate cultural
change and reduce perceptions of risk that may ultimately hinder the process of transfer? First,
the use of distribution networks and intermediaries creates efficiencies by removing choice
Box 2. BioBricks, OpenMTA, and iGEM
For more than a decade, the BioBricks Foundation (BBF) has developed legal tools and
frameworks to provide options for synthetic biologists and life science researchers gener-
ally to work in a more open, collaborative, and distributive manner. The BBF’s flagship
legal tool—the BioBrick Public Agreement, version 1.0 (BPAv1.0)—provides a frame-
work for making engineered biological sequences available for others to use. Sequences
contributed under BPAv1.0 may be accessed as information through the BBF’s website,
thereby enabling those with access to DNA synthesis capabilities to create physical bio-
materials based on these sequences. In addition, some of the sequences contributed
under BPAv1.0 have been incorporated into plasmids that may be accessed through
Addgene (https://www.addgene.org/biobrick-public-agreement-collection/).
More recently, the Open Material Transfer Agreement (OpenMTA) was developed to
specifically address the tangible rights inherent in sequences shared as physical biomate-
rials. The goal was to develop a simple, standardised MTA for sharing biological materi-
als as broadly as possible and without restriction while honouring the rights of others
and promoting safe laboratory practice and responsible research. Development of the
OpenMTA was conducted as a collaborative effort led by the BBF and the OpenPlant
Synthetic Biology Research Centre with input from researchers, social scientists, technol-
ogy transfer professionals, legal experts, business leaders, and government and funding
agencies.
Because the OpenMTA is constructed as a standard template, it can easily be incorpo-
rated into semiautomated MTA administration systems, such as Addgene’s eMTA sig-
nature system. This will help speed and simplify MTA processing while providing a less
restrictive option for material transfer when appropriate. As of this writing, the formal
review period for the OpenMTA Master Agreement is still open. Information about the
OpenMTA—including design goals, FAQs, and videos—can be accessed at OpenMTA.
org.
The iGEM Foundation, or the International Genetically Engineered Machine (iGEM),
houses a Registry of Standardised Biological Parts, which serves as the primary resource
of biomaterials. The Registry now has over 20,000 biological parts and is growing each
year. DNA sequence and other information about the biological parts in the Registry is
available online (http://parts.igem.org/Main_Page). In addition, the iGEM Foundation
shares biological parts from the Registry with academic laboratories upon request. As is
the case for the student competition, the iGEM Foundation shares biological parts with
academic labs without an MTA in place.
A requirement for biological parts to be submitted to the Registry is that the parts must
be compatible with the BioBrick RFC10 assembly standard, which is a technical standard
that enables the parts to be easily combined with one another. Today, the two organisa-
tions continue to work in partnership to support open, collaborative, and responsible
innovation in the field of synthetic biology.
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from the negotiating process, as illustrated by the Addgene example. Access to material via
Addgene is contingent on execution of the simple online agreement by the requesting institu-
tion, leaving no room for negotiation of individual terms. Contrast this with the Knockout
Mouse Consortium, in which room for individualisation remained. Another feature of such
arrangements, as illustrated by BioBricks, is reduction in the number of MTAs required for a
particular research project.
Second, the emphasis on ‘openness’ that is a hallmark of the open software movement,
from which open bioinformatics initiatives have emerged, can be translated into other areas of
biotechnology [9]. The OpenMTA is a simple, standardised agreement that enables researchers
to exchange biomaterials more freely, with features such as attribution, provenance tracking,
and ease of use internationally to work within the practical realities of technology transfer
[10].
Third, involvement in large-scale research collaborations like BioBricks builds good rela-
tionships and trust. It also aligns motivations of the parties involved. While not every TTO will
have experience in MTAs associated with large-scale collaborations, lessons can be learned
from examining the fundamental bases for the success of these larger networks in facilitating
free-flowing exchanges. Parties undertaking research with mutually beneficial outcomes are
less likely to strategize at the expense of reaching rapid agreement. Again, lack of choice is a
feature; the terms on which materials are exchanged are fixed, removing the opportunity for
TTOs to modify.
How might we translate these lessons into the world of bilateral, institutional material
transfers? Promoting exchange of materials on standardised, simple terms is an important first
step. The real challenge lies in finding a way to implement these lessons to incorporate simplic-
ity more broadly in entity-to-entity MTAs.
When is complexity needed?
There are undoubtedly circumstances where an escalation to complexity is necessary; for
instance, when commercial parties are involved and the purpose of the exchange goes beyond
research use only [3,4]. This distinction between research transfers and transfers of a commer-
cial nature is reflected in the Addgene arrangements, which include separate considerations
for industry recipients and, in accordance with the UBMTA, require written consent of the
provider for commercial use by the recipient. Many commercial parties, particularly in the
drug-development space, are likely to make significant investment into research activities
involving licensed materials and will expect some ongoing control over research outcomes and
profits. Institutional MTAs with commercial endpoints also warrant specificity with regard to
authorship and acknowledgment, reservations of rights to use materials on a continuing basis,
and allocation of profits.
There are other situations in which the nature of the material renders simplified prove-
nance documentation unsuitable, even when the material is exchanged for research purposes.
This is not to say that standardised agreements cannot be used for similar types of materials,
but their unique qualities might require the application of individual standards. Box 3 illus-
trates applicable cases. An example is research involving materials that will lead to a clinical
outcome: clear parameters will be required in MTAs of this nature because of ethical and bene-
fit-sharing issues. These issues underscore exchanges of materials provided by indigenous
donors.
Exchanges mediated by biobank intermediaries are also complicated by the fact that partici-
pants may be asked to consent not just to individual research projects that use their material
(as is normally the case) but more generally to uses that fall into the overarching purpose for
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Box 3. Tissue sourced from indigenous peoples
Sharing of tissue samples collected from indigenous participants with other researchers
may be complicated by the inclusion of culturally specific conditions within consent
agreements. Appropriately designed MTAs may facilitate culturally sensitive research
practices by enforcing consent provisions on downstream research use of the samples.
Conversely, standardised MTAs that preclude culturally specific provisions may lead to
the exclusion of indigenous groups from genetic research, either by making it too diffi-
cult to share tissue samples or by compromising trust in the research endeavour, thereby
adversely affecting indigenous participation rates. Exclusion of indigenous populations
from genetic research reduces the generalisability of resultant genomic medicine and
may exacerbate persistent health inequalities [15].
United Kingdoms Biobank
United Kingdoms Biobank was established in 2007 by a range of organisations, includ-
ing the Wellcome Trust and the UK Department of Health. It was established as a non-
profit charity and had initial funding of approximately UK£62 million. It is hosted by
the University of Manchester and supported by the UK National Health Service. UK Bio-
bank has not been designed as a ‘research project’ but rather as a key piece of scientific
infrastructure for life sciences research. UK Biobank collected biological samples from
500,000 people aged between 40 and 69 years of age. Between 2012 and 2016, 267 proj-
ects were approved for access to UK Biobank. Research groups can gain access to UK
Biobank via an authorisation process and payment of a charge. The charge is based on a
cost-recovery basis. Authorisation does not distinguish between commercial and non-
commercial research but does review the scientific validity of a project and whether it is
in the public interest. Authorisation, amongst other things, also reviews an applicant’s
ability to store and ensure the security of materials (including data). Authorised
researchers are granted limited licences to use the UK Biobank resource, and these rights
are not assignable. When researchers create additional datasets as a result of using the
UK Biobank resource, then intellectual property (IP) in these datasets is owned by the
researchers (or their institutions) [16]. Researchers are required to submit these datasets
to UK Biobank within six months following their publication, or within 12 months fol-
lowing completion of the research project. Other IP developed using the UK Biobank
resource is free from any other obligation to UK Biobank, except in one circumstance: if
use of the IP rights is deemed ‘unreasonably restrictive’ by UK Biobank, then UK Bio-
bank reserves the right to require that the IP is licensed to UK Biobank on a royalty-free,
sublicensable, and nonexclusive basis.
Transfers of sovereign genetic resources
The United Nations Convention on Biological Diversity (CBD) effectively established a
global framework for the exchange of nonhuman biological materials requiring prior
informed consent, mutually agreed terms, and equitable benefit sharing negotiated as
part of the mutually agreed terms. This is satisfied by a traditional contractual arrange-
ment between the resource provider and the party access in the form of a materials
transfer agreement. Some of the nations complying with these obligations have imple-
mented their domestic laws providing for these contracting requirements. A more com-
prehensive Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable
Sharing of Benefits Arising from their Utilisation to the Convention on Biological
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which the biobank was established. Access to biobank resources (such as the UK BioBank and
similar arrangements) for research purposes thus needs careful management, going beyond
the terms of generic MTAs. Another area of particular concern is the exchange of nonhuman
materials sourced from natural resources, for which benefit sharing is paramount. The CBD
and Nagoya Protocol attempt to provide an international framework to facilitate such
exchanges.
These examples are not exclusive but illustrate the point that there are justifiable reasons for
increasing the complexity of MTAs in some circumstances. In purely bilateral transactions,
there is considerably more scope for institutional idiosyncrasies to overtake simplicity if risk
aversion is allowed to dominate the transfer process. Many continue to adhere to a culture pro-
tecting against ‘missing out’ rather than facilitating open exchanges.
Understanding risk to overcome unreasonable aversion
Realistically, very few MTAs are likely to be monitored, and the likelihood that a risk-averse
institution would embark on the highly risky course of litigation to enforce an MTA is remote
[3]. In light of this, how might we encourage TTOs to acknowledge that simple transfer proce-
dures will be appropriate in the majority of material transfers? In order to implement real
change, the expectations of TTO personnel and the format of MTAs must change concur-
rently. This ‘combination’ of approaches has driven the success of initiatives such as Addgene,
the BioBricks Foundation, and the iGEM Foundation. Under these arrangements, simplicity is
essential. MTAs are standardised and simplified, and institutional adherence to these stan-
dards is mandated.
The success of Addgene, BioBricks and iGEM can in part be attributed to the common
interests and goals of participants—to minimise delay in research projects that require access
to research materials on reasonable terms. These common interests, originating in the open
source movement, have also driven some of the more complex arrangements for transfer of
materials for research purposes. The UK Biobank, for example, has developed strategies to
deal with the complexities associated with ethics, consent, and benefit sharing and overcome
risk aversion.
One important aspect of each of these initiatives is that they have a single gatekeeper who
plays a vital role in preventing deviations. The difficulty that universities and research insti-
tutes face is that, unlike these initiatives, there is no single body that can dictate the form of
MTA that is to have universal application for simple transfers and to manage the transfer pro-
cess. Instead, multiple institutions must be persuaded to adopt a common approach to
Diversity (Nagoya Protocol) has also been agreed setting out the mechanisms for these
contractual and benefit sharing arrangements. As might be expected, however, only a
few nations have implemented the required CBD and Nagoya Protocol laws, and the
expected benefits flowing from the benefit sharing agreements have not eventuated.
More recently, agreements directed to some agriculturally important crop plants under
the Food and Agriculture Organisation International Treaty on Plant Genetic Resources
for Food and Agriculture (Plant Treaty) and human pandemic influenza viruses under
the World Health Organisation Pandemic Influenza Preparedness Framework (PIP
Framework) have been implemented and provide for Standard Material Transfer Agree-
ments (SMTAs) with set terms and conditions of exchanges.
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practices and procedures in the execution of MTAs. This requires them to recognise deficien-
cies in the status quo. The move to standardise MTAs in the context of transfers of sovereign
genetic resources led by the United Nations, the Food and Agriculture Organisation, and the
World Health Organisation provides an example of how institutions can be drivers of change.
On a different scale, it is open to national public research funding organisations to condition
research grants on dissemination of materials using simplified processes. The NIH and AUTM
have been particularly proactive in this regard [11].
There are a number of strategies that may reduce friction in MTA negotiations and expedite
the MTA process. Applying simplicity during the process of negotiating for the transfer of
materials is crucial to eradicating risk-averse behaviour. This includes, where possible, the
removal of choice in the application of MTAs. Educating those involved in negotiating and
drafting MTAs is fundamental, particularly through utilisation of the expertise of representa-
tive bodies.
Promoting a shift in the way that ‘success’ in material transfers is perceived within institu-
tions is also essential. TTO personnel possess a surprisingly social view of their roles in pro-
moting the research agendas of their institutions [6]. This supports the proposition that
change in culture is possible, and one option for encouraging this is to invert current notions
of risk aversion for publicly funded institutions. Rather than focusing on the perceived risks
that TTOs identify in association with exchange of materials, the ‘risk’ against which TTO per-
formance should be measured is that of nonconformity with conceptions of open sharing.
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